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Abstract
The lipid-lipoprotein and oxidative stress markers in the different levels of glucose-insulin homeostasis have been studied 
in patients with metabolic syndrome (MS). 
The increase in the levels of total cholesterol (TC), triglycerides (TG), low-density lipoprotein cholesterol (LDL-C), as 
well as the decrease in High-Density Lipoprotein Cholesterol (HDL-C) was revealed to be one of the causes of hyperinsulinemia 
and insulin resistance (IR). Increased lipolysis activates the oxidative stress (OS). The leading role of TG as an indicator of high 
atherogenic potential of plasma in MS has been determined.
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Introduction
MS is now considered an interrelated combination of 
the main cardiovascular risk factors - abdominal obesity (AO), 
arterial hypertension (AH), dyslipidemia and impaired glucose 
tolerance or type 2 diabetes mellitus[1,2]. Cardiovascular 
disease, particularly coronary heart disease (CHD) is the 
leading cause of death in patients with MS [1.3.4]. There is 
evidence to support that the pathophysiological basis and the 
unifying factor of most of the symptoms described for MS, 
arise from the resistance of the peripheral tissues to insulin 
[1.5].
The main and most important risk factor for 
atherosclerosis and CHD caused by them is atherogenic lipid 
metabolism [2,3,6]. In addition to IR, hyperglycemia is of 
great importance in the genesis of dyslipidemia in MS [1,4]. 
The combination of such complex CHD risk factors aggravates 
atherogenic lipid disorders in MS [2,3,7,8].
Most researchers believe that the commonest 
manifestations of dyslipidemia combined with IR are 
hypertriglyceridemia (HT) and reduced HDL-C. An increase 
in the TC and LDL-C is less typical for MS [3,6,8,9]. In 
addition to the lipid-lipoprotein markers in the pathogenesis 
of MS, the free fatty acids (FFA) also play a major role. 
FFA  (unesterified  fatty  acids)  are  formed  by  the 
hydrolysis of TG found in the adipose tissue [1,5,10]. In the 
myocardium, the FFA are rapidly metabolized by β-oxidation 
in the mitochondria and supply the heart with 65% to 70% 
of ATP. The remaining 20-25% of myocardial ATP results 
from glucolysis [10]. During ischemia, FFA consumption 
falls, while their level increases in the plasma, which leads to 
serious consequences [1,3,5,10]. However, IR is the main risk 
associated with the elevated FFA levels [10]. It has been shown 
that MS patients have an elevated plasma FFA level, which 
results in the IR of several tissues, viz., muscle, liver, adipose, 
and endothelial cells [1,10]. Any increase in the concentration 
of FFA also leads to OS and endothelial dysfunction, which 
results in ischemia and a further increase in the concentration 
of FFA in the blood, i.e. the development of a vicious circle in 
the disease process [1,5,10].
Thus, the putative mechanisms of the relationship of the 
lipid-lipoprotein biomarkers and glucose-insulin homeostasis 
determine the necessity of studying their roles in MS.
The aim of the study was to determine the content of the 
lipid-lipoprotein biomarkers, FFAs, and the markers of OS in 
the patients with MS.
Material and Methods
A total of 80 patients (32 men and 48 women) between 
35 and 63 years of age (mean age 49.2±5.3 years) were 
included in our study. MS was diagnosed in 30 patients based 
on the criteria recommended by the experts of US National 
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Cholesterol Education Program (NCEP, 2005). The criteria 
for MS considered a waist circumference greater than 94 cm 
in men and more than 80 cm in women, blood pressure of 
130/85mmHg and above, and plasma glucose levels in the 
blood glucose, at 5.6 mmol/l or more. Control group included 
30 healthy subjects without any objective manifestations of 
MS.
The blood glucose test was performed on a fasting 
basis (fasting blood glucose, FBG). The fasting serum insulin 
level was measured by immunoenzyme assay (Beckman 
Coulter ™). Insulin resistance status was calculated using the 
homeostatic model assessment-insulin resistance (HOMA-
IR). The calculation formula employed is as follows: 
HOMA-IR = (fasting insulin [μIU/mL]×fasting blood 
glucose [mmol/L])/22.5.
During fasting, an insulin level higher than 12.5 μIU/
mL indicated a diagnosis of hyperinsulinemia, whereas those 
patients with a HOMA index above 2.27 were considered IR 
patients.
The total cholesterol (TC), high-density lipoprotein 
cholesterol (HDL-C), and triglyceride (TG) levels were 
determined in the venous blood using «Roche Reflotron Plus» 
analyzer (Germany). Low-density lipoprotein cholesterol 
(LDL-C) was calculated according to Fridvald’s formula.
Serum free fatty acid (FFA) concentrations were assayed using 
a NEFA FS kit (DiaSys, Holzheim, Germany) according to the 
manufacturer’s protocol. The intensity of lipid peroxidation in 
the blood plasma was investigated by spectrophotometry for the 
level of end-product of lipid peroxidation – malondialdehyde 
(MDA).Antioxidant protection (AOP) was studied as the total 
antioxidant activity of red blood cells and its enzymatic chain 
- by the activity of catalase (CA).
The study was approved by the Andijan State Medical 
Institute Ethics Committee. 
Statistical analysis was performed using the statistical 
software «Statistica». The mean (M) and standard error of 
the mean (SEM) were deduced. Analysis of the distribution 
of values obtained was performed using the Kolmogorov-
Smirnov test. For data with normal distribution, significance 
was assessed using Student’s t-test. Pearson’s Correlation 
Coefficient  (r)  was  used  to  determine  the  strength  of  the 
relationship between the two continuous variables. A value of 
P<0.05 was considered statistically significant.
Results and Discussion
Investigation of the lipid-lipoprotein biomarkers 
identified dyslipidemia in varying degrees of severity in all 
the MS patients.
The increased plasma TG level in MS patients, as 
well as in the whole population, remains relevant, while the 
remaining unfavorable factors determine the development of 
vascular lesions [3,8]. We detected hypercholesterolemia in 
50.2% of the patients. The average TC level in the group with 
MS patients was 6.5±0.31 mmol/l, which is 1.7-times higher 
than in the control (P<0.001) (Fig.1).
Increasing levels of LDL-C also revealed that it is 
the most aggressive fraction of cholesterol that determines 
the development of atherosclerotic vascular lesions [8,11]. 
The average LDL-C concentration in MS patients was 
5.13±0.1 mmol/l, which is 2.4-fold higher than the control 
(P<0.001)  (Fig.1).  Both  figures  are  considered  “targets  of 
hypercholesterolemia” for MS patients, as recommended by 
U.S. experts, where the cholesterol levels were significantly 
exceeded.
The value of HDL-C as the most important factor in 
antiatherosclerotic protection is proved by numerous clinical 
and experimental data [3,11,12]. Reduced HDL-C, especially 
in MS patients, has significant prognostic value with regard 
to morbidity and mortality from coronary heart disease. In 
70.2% of the MS patients examined, the HDL-C level was 
below 0.92 mmol/L (0.81 ± 0.01 mmol/l) (Fig. 1).
It is still an open question regarding the importance of 
triglycerides as an independent risk factor for atherosclerosis. 
Numerous studies have shown that the TG content can predict 
the risk of CHD, without considering other factors [1,2,3,8]. 
The plasma TG level more than any other indicator reflects the 
severity of the major clinical manifestations of MS. We found 
hypertriglyceridemia in 72.5% of the MS patients. The mean 
plasma TG concentration in MS patients was 2.8±0.07mmol/l, 
which was 2.5-fold higher than in the control (P<0.001) 
(Fig.1). Thus, the presence of hypertriglyceridemia in MS 
patients can be regarded as an indicator of high atherogenic 
potential of blood plasma.
To analyze the association between the main clinical 
manifestations of MS and the lipid-lipoprotein parameters in 
MS patients, Spearman’s rank correlation was used. 
As seen from Table 1, only the plasma TG concentration 
revealed a close relationship with the majority of clinical and 
biochemical parameters of the patients with MS, examined. 
There were statistically significant correlations between the 
TG content and important clinical characteristics of MS: 
diastolic blood pressure, fasting glucose levels and waist 
circumference (WC).
Figure 1. Lipid-lipoprotein biomarkers in patients with MS
Table 1.
The correlations between TG levels and clinical parameters in 
patients with MS
TG
Indicators r p
Diastolic blood pressure 0.681 0.027
WC 0.435 0.043
Fasting glucose 0.421 0.046
TC  0.695 <0.001
HDL-C  -0.437 0.029
LDL / HDL-C 0.549 0.00821 N. R. Uzbekova / International Journal of BioMedicine 4(1) (2014) 19-22
It was interesting to observe when a strong positive 
correlation was detected between the TG content and diastolic 
blood pressure levels. The probable point of view taken is that 
the development of hypertension and hypertriglyceridemia is 
determined by the presence of IR and the structural features 
of the skeletal muscles [11]. From this point of view, the 
relationships found between TG and WC, TG and DBP, as well 
as the positive relationship between DBP and BMI (r=0.560; p 
=0.004) could be interpreted as an indirect confirmation of the 
common pathophysiological roots of AH, AO and HT.
We have found a direct correlation between the TG 
content and the other atherogenic factors (TC, HDL-C, and 
the LDL-C/HDL-C ratio) as well as a negative correlation 
between TG and HDL-C. In the analysis of the plasma lipid 
profile, based on the TG level in MS patients, we found that 
patients with HT had significantly higher levels of TC and LDL-C. 
A positive correlation relationship between the TG 
content and WC is legitimate. The WC and WC/HC (hip 
circumference) ratio are the most sensitive indicators of the 
severity of AO and atherosclerotic changes. Enhanced lipolysis, 
which is typical for AO and the atherosclerotic process, is 
accompanied by an increase in the FFA concentration in the 
portal vein blood that leads to the increased secretion of TG-
rich very-LDL-C [3,8,12].
Based on the results of the regression analysis, it can 
be argued that, when the WC/HC ratio >1.0, the plasma 
HDL-C  concentration  is  significantly  decreased  (0.91±0.02 
and 0.80±0.01 mmol/L; p=0.031), showing a trend toward 
an increased plasma TG level (1.99±0.09 and 2.39±0.11 
mmol/L; p=0.071), which is detected. The changes detected 
were independent of patient age, duration of MS, the degree 
of control of carbohydrate metabolism and BMI. The results 
obtained suggest a close relationship between AO and 
hypertriglyceridemia in MS patients. 
The positive correlations between the plasma TG content 
and fasting glucose indicate an increase in the atherogenic 
properties of the plasma with deterioration in the control of the 
carbohydrate metabolism, which is, in turn, associated with a 
reduction in the lipoprotein lipase activity.
The violation of blood transport and FFA uptake by 
the cells precedes IR formation.  In MS patients, we found 
a  significant  increase  in  the  plasma  FFA  level,  by  up  to 
0.87±0.19 mmol/l (2.4-fold) (P<0.001) (Fig. 2).
 
Consequently, the functioning of the insulin receptors, the 
secondary system of signal transmission and glucose uptake 
by the cells are broken. Hyperglycemia and increased FFA 
level are accompanied by hyperinsulinemia. The insulin level 
in the blood increases to 19.6±1.72 μIU/mL (Fig. 2). The 
violation of the lipid-transport pathway causes the changes 
in the carbohydrate homeostasis and MS development. The 
adaptation of cells to this type of transport activates the FFA 
lipolysis and enhances the insulin secretion, which results 
in hyperinsulinemia. The violation of the receptor-mediated 
FFA transport, causing a change in the structure of the cell 
membranes, is the basis of IR formation and hyperinsulinemia 
[1,2,4,6]. Elevated FFA levels cause the overproduction of the 
mitochondrial reactive oxygen species which leads to LDL-C 
oxidation and induces an inflammatory process [4,10].
Excess hypertriglyceridemia and FFA in the blood 
activate radical formation and lipid peroxidation, which 
contribute to the peroxide modification of the LDL-C. The 
oxidized LDL-C then damages the endothelium, increases 
its permeability, and causes the endothelial dysfunction by 
developing vasoconstriction [13]. Arteriole narrowing leads to 
tissue ischemia, energy shortages and further activation of the 
lipid peroxidation [1,9]. 
The study of the lipid peroxidation activity in the MS 
patients showed that the plasma level of MDA, which is the 
product of peroxidation, was increased by 2.2-fold (P<0.001) 
(Fig. 3). In a study of the anti-radical potential, the reduced 
activity of  catalase to 37.6% caught our attention (P<0.001) 
(Fig. 3). In the study of the anti-radical potential of the plasma, 
catalase activity reduced by 37.6% was found, which was the 
main enzyme involved in anti-radical protection. Therefore, in 
MS patients, the activation of lipid peroxidation is associated 
with a reduction in the antioxidant potential.
Conclusion
MS is associated with a significant impairment of the 
lipid-lipoprotein plasma biomarkers: increased levels of the 
plasma TG, FFAs, and LDL-C and a decrease in HDL-C level. 
The plasma TG level, more than any other indicator, reflects 
the severity of the major clinical manifestations of MS: AO, 
AH and decompensation of the carbohydrate metabolism. 
Hypertriglyceridemia in MS patients is most often associated 
with lipid metabolism disorders such as high TC, LDL-C, and 
FFAs levels. The presence of HT in the MS patients can be 
considered as an indicator of the high atherogenic potential 
of the blood plasma. The dysfunction of the lipid biomarkers 
          Figure 2. Indicators of FFA and glucose homeostasis in  
            patients with MS
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activates the OS with an increase in the lipid peroxidation and 
a decrease in the antioxidant defenses. 
Therefore, we can conclude that the lipid-lipoprotein 
biomarkers and OS markers are component parts of MS.
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